Sharps Technology (STSS) Competitors $0.36 -0.16 (-31.45%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.38 +0.02 (+5.34%) As of 02/21/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends STSS vs. PSTV, STRR, CTCX, NUWE, CHEK, TNON, SINT, TTOO, HSCS, and AMIXShould you be buying Sharps Technology stock or one of its competitors? The main competitors of Sharps Technology include Plus Therapeutics (PSTV), Star Equity (STRR), Carmell (CTCX), Nuwellis (NUWE), Check-Cap (CHEK), Tenon Medical (TNON), Sintx Technologies (SINT), T2 Biosystems (TTOO), Heart Test Laboratories (HSCS), and Autonomix Medical (AMIX). These companies are all part of the "medical equipment" industry. Sharps Technology vs. Plus Therapeutics Star Equity Carmell Nuwellis Check-Cap Tenon Medical Sintx Technologies T2 Biosystems Heart Test Laboratories Autonomix Medical Plus Therapeutics (NASDAQ:PSTV) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Does the media refer more to PSTV or STSS? In the previous week, Plus Therapeutics had 4 more articles in the media than Sharps Technology. MarketBeat recorded 4 mentions for Plus Therapeutics and 0 mentions for Sharps Technology. Plus Therapeutics' average media sentiment score of 0.16 beat Sharps Technology's score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Plus Therapeutics Neutral Sharps Technology Neutral Does the MarketBeat Community believe in PSTV or STSS? Plus Therapeutics received 67 more outperform votes than Sharps Technology when rated by MarketBeat users. However, 100.00% of users gave Sharps Technology an outperform vote while only 62.39% of users gave Plus Therapeutics an outperform vote. CompanyUnderperformOutperformPlus TherapeuticsOutperform Votes6862.39% Underperform Votes4137.61% Sharps TechnologyOutperform Votes1100.00% Underperform VotesNo Votes Do analysts recommend PSTV or STSS? Plus Therapeutics currently has a consensus price target of $13.50, suggesting a potential upside of 1,025.00%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Plus Therapeutics is more favorable than Sharps Technology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Sharps Technology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PSTV or STSS more profitable? Sharps Technology has a net margin of 0.00% compared to Plus Therapeutics' net margin of -225.07%. Plus Therapeutics' return on equity of 0.00% beat Sharps Technology's return on equity.Company Net Margins Return on Equity Return on Assets Plus Therapeutics-225.07% N/A -154.56% Sharps Technology N/A -110.40%-73.60% Which has more risk & volatility, PSTV or STSS? Plus Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Which has preferable earnings & valuation, PSTV or STSS? Sharps Technology has lower revenue, but higher earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus Therapeutics$4.91M1.44-$13.32M-$2.53-0.47Sharps TechnologyN/AN/A-$9.84M-$8.08-0.04 Do institutionals and insiders believe in PSTV or STSS? 3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 5.5% of Plus Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Sharps Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryPlus Therapeutics beats Sharps Technology on 10 of the 17 factors compared between the two stocks. Get Sharps Technology News Delivered to You Automatically Sign up to receive the latest news and ratings for STSS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STSS vs. The Competition Export to ExcelMetricSharps TechnologySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.96M$4.71B$5.84B$9.15BDividend YieldN/A39.90%4.75%3.85%P/E Ratio-0.0427.4125.4719.00Price / SalesN/A53.20447.5876.30Price / CashN/A51.1038.0134.83Price / Book0.036.577.644.62Net Income-$9.84M$90.13M$3.18B$245.85M7 Day Performance1.71%-2.20%-1.99%-2.68%1 Month Performance-81.06%-2.17%-0.42%-2.19%1 Year PerformanceN/A15.26%16.51%12.84% Sharps Technology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STSSSharps Technology0.2888 of 5 stars$0.36-31.4%N/AN/A$1.96MN/A-0.043Gap DownPSTVPlus Therapeutics2.7842 of 5 stars$1.22-1.3%$13.50+1,006.5%-40.9%$7.20M$4.91M-0.4820News CoverageSTRRStar Equity1.0421 of 5 stars$2.11+2.4%N/A-53.9%$6.79M$45.78M-0.82460CTCXCarmellN/A$0.28-9.2%N/A-92.2%$5.90MN/A0.0014NUWENuwellis1.8145 of 5 stars$1.33+4.7%$17.00+1,178.2%-94.0%$5.81M$8.86M-0.0170News CoverageGap UpCHEKCheck-Cap0.4459 of 5 stars$0.90-2.2%N/A-68.1%$5.27MN/A-0.3080Analyst ForecastTNONTenon Medical1.6786 of 5 stars$1.46-2.3%$5.50+278.0%+23.0%$4.57M$2.93M-0.058SINTSintx Technologies1.0079 of 5 stars$3.06-5.6%N/A-82.2%$4.10M$2.63M-0.0640News CoverageTTOOT2 Biosystems1.9565 of 5 stars$0.19-7.4%$5.00+2,472.0%-96.8%$4.09M$7.68M0.00180Analyst ForecastNews CoverageHigh Trading VolumeHSCSHeart Test Laboratories2.4807 of 5 stars$3.59-5.5%$13.50+276.0%-69.2%$3.52M$20,000.00-0.4510Positive NewsGap DownAMIXAutonomix Medical1.8698 of 5 stars$2.72+0.7%$28.00+929.4%-96.2%$3.13MN/A-0.171News Coverage Related Companies and Tools Related Companies Plus Therapeutics Competitors Star Equity Competitors Carmell Competitors Nuwellis Competitors Check-Cap Competitors Tenon Medical Competitors Sintx Technologies Competitors T2 Biosystems Competitors Heart Test Laboratories Competitors Autonomix Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:STSS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sharps Technology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sharps Technology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free STSS Stock Alerts